Trial · NCT02497612
Participant flow32
How many started, completed or left each group, period by period.
1 to 20 of 32
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Ferroquine (up to 400 mg) + Artefenomel (up to 800 mg) | 93 | |
| Overall Study | STARTED | Ferroquine (up to 600 mg) + Artefenomel (up to 800 mg) | 94 | |
| Overall Study | STARTED | Ferroquine (up to 900 mg) + Artefenomel (up to 800 mg) | 97 | |
| Overall Study | STARTED | Ferroquine (up to 1200 mg) + Artefenomel (up to 800 mg) | 93 | |
| Overall Study | Treated | Ferroquine (up to 400 mg) + Artefenomel (up to 800 mg) | 92 | |
| Overall Study | Treated | Ferroquine (up to 600 mg) + Artefenomel (up to 800 mg) | 94 | |
| Overall Study | Treated | Ferroquine (up to 900 mg) + Artefenomel (up to 800 mg) | 96 | |
| Overall Study | Treated | Ferroquine (up to 1200 mg) + Artefenomel (up to 800 mg) | 91 | |
| Overall Study | Cohort 1: >14 Years to <70 Years | Ferroquine (up to 400 mg) + Artefenomel (up to 800 mg) | 14 | |
| Overall Study | Cohort 1: >14 Years to <70 Years | Ferroquine (up to 600 mg) + Artefenomel (up to 800 mg) | 15 | |
| Overall Study | Cohort 1: >14 Years to <70 Years | Ferroquine (up to 900 mg) + Artefenomel (up to 800 mg) | 18 | |
| Overall Study | Cohort 1: >14 Years to <70 Years | Ferroquine (up to 1200 mg) + Artefenomel (up to 800 mg) | 16 | |
| Overall Study | Cohort 2: >5 Years to <=14 Years | Ferroquine (up to 400 mg) + Artefenomel (up to 800 mg) | 6 | |
| Overall Study | Cohort 2: >5 Years to <=14 Years | Ferroquine (up to 600 mg) + Artefenomel (up to 800 mg) | 5 | |
| Overall Study | Cohort 2: >5 Years to <=14 Years | Ferroquine (up to 900 mg) + Artefenomel (up to 800 mg) | 6 | |
| Overall Study | Cohort 2: >5 Years to <=14 Years | Ferroquine (up to 1200 mg) + Artefenomel (up to 800 mg) | 5 | |
| Overall Study | Cohort 3: >2 Years to <=5 Years | Ferroquine (up to 400 mg) + Artefenomel (up to 800 mg) | 66 | |
| Overall Study | Cohort 3: >2 Years to <=5 Years | Ferroquine (up to 600 mg) + Artefenomel (up to 800 mg) | 66 | |
| Overall Study | Cohort 3: >2 Years to <=5 Years | Ferroquine (up to 900 mg) + Artefenomel (up to 800 mg) | 67 | |
| Overall Study | Cohort 3: >2 Years to <=5 Years | Ferroquine (up to 1200 mg) + Artefenomel (up to 800 mg) | 65 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02497612/flow